


**Curriculum Vitae of Associate Professor Jacqueline Anne Palace**

---

**Personal Information**

**Date of Birth** 17 June 1960  
**Work Address** Department of Clinical Neurology  
Level 3, West Wing  
John Radcliffe Hospital  
Headley Way  
Oxford, OX3 9DU  
**Tel** c/o Joy Hodder 01865 231907  
**Email** [jacqueline.palace@ndcn.ox.ac.uk](mailto:jacqueline.palace@ndcn.ox.ac.uk)  
**Other** General Medical Council Membership Number: 175676  
Medical Protection Society Membership Number: 2821245  
Good Clinical Practice: updated October 2017



---

**Qualifications**

1983 BM (Honours) and Clinical Distinction (Southampton)  
1986 MRCP (UK)  
1992 DM (Southampton)  
1995 Accredited in Neurology  
2000 FRCP (UK)

**Current Position and Professional Roles**

- Consultant Neurologist, Oxford University Hospital Trust
- Associate Professor, University of Oxford
- Clinical Lead, Nationally Commissioned Neuromyelitis Optica Service
- Clinical Lead, Nationally Commissioned Myasthenia Service
- Clinical Lead, Oxford Multiple Sclerosis Group
- Clinical Lead, Department of Health MS DMT Risk Sharing Scheme (1992-2007)

**Professional Membership/Other Honours**

- Board Member, European Charcot Foundation
- Steering Committee Member, MAGNIMS
- Oxford Lead, European Rare Network for Neuromuscular Diseases
- Elected Member, Association of British Neurologists (May 2016-May 2019)
- Member, Guthy Jackson Foundation Clinical Consortium
- Clinical Advisory Board, Cochrane UKCC
- Honorary Fellow, Hong Kong Multiple Sclerosis Society
- Member, British Medical Association

## Research

### Interests

Research interests cover MS, NMO, CMS, Myasthenia Gravis and include clinical trials, immunological studies, pathology, biomarkers, genetics and imaging studies.

### Impact and Contribution

- H index factor: 53
- 84 publications over the last 4 years
- DPhil/PhD Supervisor: 7 ongoing
- Supervisor to visiting international fellows: 3 ongoing

### Recent Notable Publications

Palace J, Duddy M, Lawton M, et al. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. *J Neurol Neurosurg Psychiatry* Published Online First: 21 September 2018. doi: 10.1136/jnnp-2018-318360

Jurynczyk, M., Messina, S., Woodhall, M., Raza, N., Everett, R., Roca-Fernandez, A., Tackley, G., Hamid, S., Sheard, A., Reynolds, G., Chandratre, S., Hemingway, C., Jacob, A., Vincent, A., Leite, M., Waters, P. and Palace, J. (2018). *Clinical presentation and prognosis in MOG-antibody disease: a UK study.*

Jurynczyk M, Geraldles R, Probert F, Woodhall M, Waters P, Tackley G, DeLuca G, Chandratre S, Leite MI, Vincent A, Palace J. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. *Brain* 2017;140(3):617-627

Jurynczyk M, Tackley G, Kong Y, Geraldles R, Matthews L, Woodhall M, . . . Palace J. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. *J Neurol Neurosurg Psychiatry*, 2017;88(2):132-136